High glucose inhibits receptor activator of nuclear factorκB ligand-induced osteoclast differentiation via downregulation of vATPase V0 subunit d2 and dendritic cellspecific transmembrane protein

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 865-870

  Xu, Juan ^a,b   Yue, Feng ^b   Wang, Jingbo ^b   Chen, Li ^a   Qi, Wenbo ^b  

^a SHANDONG UNIVERSITY   (China)

^b TAIAN CITY CENTRAL HOSPITAL   (China)

Author keywords

Dendritic cellspecific transmembrane protein; Diabetes; Osteoclast differentiation; V ATPase V0 subunit d2

Indexed keywords

ATP6V0D2 PROTEIN, MOUSE; DC-STAMP PROTEIN, MOUSE; GLUCOSE; MEMBRANE PROTEIN; MESSENGER RNA; NERVE PROTEIN; NFATC1 PROTEIN, MOUSE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; TRANSCRIPTION FACTOR NFAT;

ANIMAL; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; OSTEOCLAST; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DOWN-REGULATION; GLUCOSE; MEMBRANE PROTEINS; MICE; NERVE TISSUE PROTEINS; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; RNA, MESSENGER; SIGNAL TRANSDUCTION; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84916230499     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2807     Document Type: Article

References (48)

1. Xu Y, Wang L, He J, et al: Prevalence and control of diabetes in Chinese adults. JAMA 310: 948-959, 2013.
2. Khazai NB, Beck GR Jr and Umpierrez GE: Diabetes and fractures: an overshadowed association. Curr Opin Endocrinol Diabetes Obes 16: 435-445, 2009.
3. Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M and Fukagawa M: Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 40: 1408-1414, 2007.
4. Fujii H, Hamada Y and Fukagawa M: Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats. Bone 42: 372-379, 2008.
5. Gaudio A, Privitera F, Battaglia K, et al: Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 97: 3744-3750, 2012.
6. Wittrant Y, Gorin Y, Woodruff K, et al: High d(+) glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 42: 1122-1130, 2008.
7. Xu F, Ye YP, Dong YH, Guo FJ, Chen AM and Huang SL: Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. J Huazhong Univ Sci Technolog Med Sci 33: 244-249, 2013.
8. Kaneko H, Sasaki T, Ramamurthy NS and Golub LM: Tetracycline administration normalizes the structure and acid phosphatase activity of osteoclasts in streptozotocin-induced diabetic rats. Anat Rec 227: 427-436, 1990.
9. Hamada Y, Fujii H, Kitazawa R, Yodoi J, Kitazawa S and Fukagawa M: Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. Bone 44: 936-941, 2009.
10. Reyes-García R, Rozas-Moreno P, López-Gallardo G, García-Martín A, Varsavsky M, Avilés-Perez MD and Muñoz-Torres M: Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol 50: 47-52, 2013.
11. Dienelt A and zur Nieden NI: Hyperglycemia impairs skeletogenesis from embryonic stem cells by affecting osteoblast and osteoclast differentiation. Stem Cells Dev 20: 465-474, 2011.
12. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999.
13. Kim K, Lee SH, Ha Kim J, Choi Y and Kim N: NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 22: 176-185, 2008.
14. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999.
15. Asagiri M and Takayanagi H: The molecular understanding of osteoclast differentiation. Bone 40: 251-264, 2007.
16. Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature 423: 337-342, 2003.
17. Yamashita T, Yao Z, Li F, et al: NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282: 18245-18253, 2007.
18. Teitelbaum SL and Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649, 2003.
19. Yagi M, Miyamoto T, Sawatani Y, et al: DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202: 345-351, 2005.
20. Lee SH, Rho J, Jeong D, et al: v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12: 1403-1409, 2006.
21. Yagi M, Ninomiya K, Fujita N, et al: Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J Bone Miner Res 22: 992-1001, 2007.
22. Suzuki K, Kurose T, Takizawa M, et al: Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Res Clin Pract 68: 117-125, 2005.
23. Hie M, Yamazaki M and Tsukamoto I: Curcumin suppresses increased bone resorption by inhibiting osteoclastogenesis in rats with streptozotocin-induced diabetes. Eur J Pharmacol 621: 1-9, 2009.
24. Rio DC, Ares M Jr, Hannon GJ and Nilsen TW: Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc 2010: 5439, 2010
25. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ and Wagner EF: Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24: 184-187, 2000.
26. Wagner EF and Karsenty G: Genetic control of skeletal development. Curr Opin Genet Dev 11: 527-532, 2001.
27. Takayanagi H, Kim S, Koga T, et al: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901, 2002.
28. Matsuo K, Galson DL, Zhao C, et al: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 279: 26475-26480, 2004.
29. Ishida N, Hayashi K, Hoshijima M, et al: Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277: 41147-41156, 2002.
30. Gandhi A, Doumas C, O'Connor JP, Parsons JR and Lin SS: The effects of local platelet rich plasma delivery on diabetic fracture healing. Bone 38: 540-546, 2006.
31. Verhaeghe J, Suiker AM, Visser WJ, Van Herck E, Van Bree R and Bouillon R: The effects of systemic insulin, insulinlike growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. J Endocrinol 134: 485-492, 1992.
32. Hamada Y, Fujii H, Kitazawa R, Yodoi J, Kitazawa S and Fukagawa M: Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. Bone 44: 936-941, 2009.
33. Fujii H, Hamada Y and Fukagawa M: Bone formation in spontaneously diabetic Torii-newly established model of nonobese type 2 diabetes rats. Bone 42: 372-379, 2008.
34. Dougall WC, Glaccum M, Charrier K, et al: RANK is essential for osteoclast and lymph node development. Genes Dev 13: 2412-2424, 1999.
35. Kong YY, Yoshida H, Sarosi I, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323, 1999.
36. Wagner EF and Eferl R: Fos/AP-1 proteins in bone and the immune system. Immunol. Rev 208: 126-140, 2005.
37. Wang ZQ, Ovitt C, Grigoriadis AE, Möhle-Steinlein U, Rüther U and Wagner EF: Bone and haematopoietic defects in mice lacking c-fos. Nature 360: 741-745, 1992.
38. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA and Wagner EF: c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448, 1994.
39. Matsuo K, Galson DL, Zhao C, et al: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. Biol Chem 279: 26475-26480, 2004.
40. Teitelbaum SL: Bone resorption by osteoclasts. Science 289: 1504-1508, 2000.
41. Yagi M, Miyamoto T, Toyama Y and Suda T: Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab 24: 355-358, 2006.
42. Feng X and McDonald JM: Disorders of bone remodeling. Annu Rev Pathol 6: 121-145, 2011.
43. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C and Henriksen K: Are nonresorbing osteoclasts sources of bone anabolic activity? Bone Miner Res 22: 487-494, 2007.
44. Burr DB, Miller L, Grynpas M, et al: Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 33: 960-969, 2003.
45. Li J, Sato M, Jerome C, Turner CH, Fan Z and Burr DB: Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene. J Bone Miner Metab 23: 48-54, 2005.
46. Ma L, Oei L, Jiang L, et al: Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 27: 319-332, 2012.
47. Vestergaard P: Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-A meta-analysis. Osteoporos Int 18: 427-444, 2006.
48. Janghorbani M, Van Dam RM, Willett WC and Hu FB: Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166: 495-505, 2007.